L-Type amino acid transporter 1 (LAT1) is overexpressed in malignant tumor cells to support their growth and proliferation. BCH is a LAT1 inhibitor that inhibits the uptake of [14C]L-leucine (1μM) in KB, Saos2, and C6 cells with IC50 values of 75.3±6.7μM, 78.8±3.5μM, and 73.1±4.5μM, respectively. BCH also exhibited anti-proliferative effects on KB, Saos2, and C6 cells with IC50 values of 6.9±0.4mM, 5.6±0.7mM, and 6.5 ± 0.9mM, respectively. Treatment of cancer cells with 20 mM BCH significantly increased the proportion of TUNEL-positive cells in comparison to the untreated groups. BCH treatment also significantly promoted proteolytic cleavage of procaspase-7 and procaspase-3 in cancer cells.[1] Treatment of primary mouse hepatocytes with 10mM BCH led to 38% and 50% increase in cellular and extracellular levels of glutamate, respectively. In normal C57BL/6J mice, treatment with 0.7g/kg BCH for 6 hr significantly increased glutamate level, glutamate dehydrogenase activity, and NAD+/NADH ratio in the liver. In mice fed with high fat/high fructose western diet, peritoneal injection of BCH (0.7g/kg/day) for 8 weeks reduced the level of triglyceride by 30% compared to the control group. BCH treatment also reduced high fat/high fructose diet-induced stress, inflammation and ameliorated hepatic injury and hyperglycemia in mice.[2]
作用机制
BCH is a selective LAT1 inhibitor that can suppress cell growth and induce apoptosis.[1]
搜索
